Start-Up Previews (07/2010)
Executive Summary
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Alzheimer's Start-Ups Face A Discovery And Clinical Crossroads," features profiles of AlzProtect, Axerion Therapeutics, Cognition Therapeutics and Galantos Pharma. "The Future of Laparoscopy: Single Incision, NOTES And Robots," features profiles of EndoControl, Ovesco Endoscopy, SurgiQuest and Virtual Incision. Plus these Start-Ups Across Health Care: Antabio, Beta-Stim, CMP Therapeutics, Elixir Medical, Kerecis, Optivia Biotechnology, Quanterix and reinnervate.
You may also be interested in...
Elixir Medical Corp.
Elixir Medical Corp. aims to address the shortcomings of current drug-eluting stents, such as late stent thrombosis, dual antiplatelet therapy duration and better efficacy in more complex disease. Elixir's technology innovations include what it describes as the thinnest durable biocompatible polymer coating, an ultra-thin biodegradable polymer coating and a fully biodegradable drug eluting stent.
Axerion Therapeutics Inc.
Axerion Therapeutics Inc.'s technology aims to block the binding of Amyloid beta to the prion protein PrP-C, a mechanism its scientists say is the toxic trigger behind neuronal death in Alzheimer's disease. Based at Yale University in New Haven, the team found that mice with AB plaques but no PrP-C showed no cognitive impairment. (Also see "Axerion Therapeutics Inc." - Scrip, 1 Jul, 2010.)
Optivia Biotechnology Inc.
Optivia Biotechnology Inc. is positioned to help drug developers address clinically significant transporter-related drug-drug interactions. In addition to its polarized mammalian cell assay, it is developing a platform for studying transporter biology and optimizing drug discovery and development.